Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis
Quan Rao, Min� Li, Wei Xu, et al.
Hepatology International (2020) Vol. 14, Iss. 5, pp. 765-775
Closed Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
Tianyu Tang, Xing Huang, Gang Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 350
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
Meiyan Zhu, Ze-Long Liu, Shuling Chen, et al.
Hepatology (2024) Vol. 80, Iss. 4, pp. 807-815
Closed Access | Times Cited: 15
Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review
Maryam Noori, Farideh Jafari‐Raddani, Zeinab Davoodi‐Moghaddam, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer
Zelin Hou, Yu Pan, Qinglin Fei, et al.
Journal of Cancer Research and Clinical Oncology (2020) Vol. 147, Iss. 2, pp. 517-531
Open Access | Times Cited: 54
Assessing PD-L1 Expression Level via Preoperative MRI in HCC Based on Integrating Deep Learning and Radiomics Features
Yuchi Tian, Temitope Emmanuel Komolafe, Jian Zheng, et al.
Diagnostics (2021) Vol. 11, Iss. 10, pp. 1875-1875
Open Access | Times Cited: 29
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. e82-e158
Closed Access
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Kurzversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. 169-203
Closed Access
S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Kurzversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. 293-336
Closed Access
S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. e159-e260
Closed Access
Effectiveness and safety of angiogenesis inhibitors combined with PD-1/PD-L1 blockades in the first-line treatment of patients with advanced hepatocellular carcinoma: A single-center retrospective study
Jing Xu, Xin Wang, Zhenya Jia, et al.
Medicine (2025) Vol. 104, Iss. 11, pp. e41814-e41814
Open Access
Self-supervised contrastive learning using CT images for PD-1/PD-L1 expression prediction in hepatocellular carcinoma
Tianshu Xie, Yi Wei, Lifeng Xu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 10
S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 01, pp. e67-e161
Open Access | Times Cited: 3
S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 02, pp. e213-e282
Open Access | Times Cited: 3
Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
Wen Wen, Yong Zhang, Hua Zhang, et al.
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 3, pp. 969-978
Closed Access | Times Cited: 15
Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis
Qing Lei, Xin Yan, Huimin Zou, et al.
Discover Oncology (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 14
Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world
Jin-Kai Feng, Zong‐Han Liu, Zhigang Fu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 13
Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy
Shida Pan, Yingying Yu, Siyu Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study
Jian-Xu Li, Wen-Xiang Deng, Shi‐Ting Huang, et al.
Radiation Oncology (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 12
S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 02, pp. 231-260
Open Access | Times Cited: 2
An overview: Management of patients with advanced hepatocellular carcinoma
Jincheng Wang, Rui Wu, Jin-Yu Sun, et al.
BioScience Trends (2022) Vol. 16, Iss. 6, pp. 405-425
Open Access | Times Cited: 11
Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China
Xiao-Qi Chen, Yun-Xia Zhao, Chuanlei Zhang, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1483-1493
Open Access | Times Cited: 10
S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 01, pp. 73-109
Open Access | Times Cited: 1
Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma
Xinrui Wang, Jihan Huang, Yixiao Liu, et al.
European Journal of Clinical Pharmacology (2024)
Closed Access | Times Cited: 1
Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review
Jingxin Yan, Manjun Deng, Shunyu Kong, et al.
iLiver (2022) Vol. 1, Iss. 4, pp. 225-234
Closed Access | Times Cited: 7
Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review
Zun-Yi Zhang, Erlei Zhang, Bixiang Zhang, et al.
World Journal of Gastrointestinal Surgery (2021) Vol. 13, Iss. 8, pp. 796-805
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top